SUBMISSIONS: 428 ATTENDEES: 562
ATTENDEES | LECT CT | |
---|---|---|
1 |
David Barczak |
1 |
2 |
Eric Greska |
1 |
3 |
Sujata Bhatia |
4 |
4 |
Roger Kobak |
1 |
5 |
Carlos Asarta |
1 |
6 |
Ryan Beveridge |
1 |
7 |
Ann Bell |
2 |
8 |
Amy Griffin |
2 |
9 |
Patricia Walsh |
1 |
10 |
Catherine Heilferty |
1 |
11 |
Sarah Rooney |
1 |
12 |
Anna Klintsova Maybe you are aware that NIH-funded researchers in the University of Delaware are currently scrutinized and under attack by PETA. This is not a unique situation – many scientists across the nation find themselves in such situation. Are are you planning any NEW initiatives to protect and support your fellow researchers? |
2 |
13 |
Michele Lobo |
1 |
14 |
Bryan Crissinger |
1 |
15 |
Darryn McCauley What is your opinion on the future of regulation for the gene editing technology, Crispr, particularly in light of last year’s announcement of the first genetically edited babies born in China last year? |
1 |
16 |
Thomas Buckley |
1 |
17 |
Katarina Smiljanec |
1 |
18 |
Tracey Bryant |
1 |
19 |
Karyn Stockar |
2 |
20 |
Anshuman Razdan |
1 |
21 |
Harry Dillner |
2 |
22 |
Jennifer Graber |
1 |
23 |
Mary Dozier |
4 |
24 |
Karen Rosenberg |
4 |
25 |
Dave Edwards |
1 |
26 |
Ryan Zurakowski |
1 |
27 |
Fabrice Veron |
2 |
28 |
Tiffany Doherty |
1 |
29 |
Cathy Wu |
1 |
30 |
Anna Klintsova |
4 |
31 |
Jennifer Sims-Mourtada |
2 |
32 |
Mohsen Badiey |
1 |
33 |
Christopher Price |
1 |
34 |
John Koh |
1 |
35 |
Maria Aristigueta |
1 |
36 |
Jennifer Carrano |
1 |
37 |
Helene Intraub |
2 |
38 |
Changqing Wu Will the research on prevention of cancer or other chronic diseases receive increased attention in NIH funding? Will NIH focus more on disease treatment rather than prevention? |
1 |
39 |
Randall Duncan |
1 |
41 |
Ramona Neunuebel What initiatives should universities focus on to ultimately increase the participation of underrepresented minorities in biomedical workforce? |
4 |
42 |
Fidelma Boyd |
3 |
43 |
Roghayeh (Leila) Barmaki |
1 |
44 |
David Burris |
1 |
45 |
Zhihao Zhuang |
1 |
46 |
Lorraine Phillips |
1 |
47 |
Babatunde Ogunnaike |
2 |
48 |
Alexandra Turano |
1 |
49 |
Mary Beth Bielicki |
1 |
50 |
Cecilia Arighi |
1 |
51 |
Jennifer Sims-Mourtada |
2 |
52 |
Cheng-shun Fang |
2 |
53 |
Sharon Rozovsky Sharon |
4 |
54 |
John Jeka |
1 |
55 |
Alenka Hlousek-Radojcic |
1 |
56 |
Felicia Berube |
1 |
57 |
Xiaolong Li |
1 |
58 |
Martha Buell |
2 |
59 |
Jaclyn Schwarz |
1 |
60 |
Tanya Haley |
2 |
61 |
Emily Day |
1 |
62 |
Adam Foley I’d be curious to hear the thoughts of both individuals regarding the future research funding and legislative action for comprehensive sex education in light of continued research indicating the ineffectiveness of abstinence only education. Thank you. |
1 |
63 |
Josh Neunuebel |
1 |
64 |
Rebecca Boyer-Andersen |
1 |
65 |
Rebecca Della Valle |
1 |
66 |
Julie Frieswyk |
2 |
67 |
Michele D’Agata |
1 |
68 |
Rahmat Beheshti The University of Delaware is highly active in biomedical research with many NIH funded projects. However, some of the Program Officers at NIH are less familiar with the universities that do not have their own medical schools. Delaware is one of the five states in the US that doesn’t have a medical school. While NIH has great programs such as IDeA to support research in under-resourced states, are there similar initiatives at NIH to further promote supporting research at such universities? |
1 |
69 |
Jeremy Crenshaw |
1 |
70 |
Ian Chrisman |
1 |
72 |
Darcy Reisman |
1 |
71 |
Tania Roth Biomedical research and ending experimentation on nonhuman animals is now a top priority of PETA. Several NIH supported scientists, including here at UD, are currently being harassed with attacks that are ill-informed and extremely damaging. PETA is being allowed to dominate public discourse. Why? To protect the basic and biomedical research enterprises, it seems critical that NIH take a public stand for nonhuman animal research and the scientists conducting the research. |
1 |
72 |
Kelvin Lee |
1 |
73 |
Brian Bahnson |
1 |
74 |
Salil Lachke |
2 |
75 |
Brittany Osborne |
1 |
76 |
Pamela Green |
4 |
77 |
Morgan Sherer |
1 |
78 |
Janet Johnson |
2 |
79 |
Kali Kniel |
3 |
80 |
Adele Hayes |
1 |
81 |
Prasad Dhurjati |
3 |
82 |
Kristi Kiick |
1 |
83 |
Carol Bedgar |
1 |
84 |
dawn fallik |
4 |
85 |
Matthew Oliver What is a person, physically, ecologically, socially, and spiritually? Do these answers shape our medical practice? |
1 |
86 |
Edward O’Donnell |
1 |
87 |
David Ermann |
2 |
88 |
Stephen Bowman In what ways can we leverage Lifestyle Medicine to prevent, treat and reverse chronic disease through focusing on: a predominantly whole food, plant-based diet, regular physical activity, adequate sleep, stress management, avoidance of risky substance use, and other non-drug modalities, to prevent, treat, and, oftentimes, reverse the lifestyle-related, chronic disease that’s all too prevalent? https://www.lifestylemedicine.org/ |
2 |
89 |
Mona Batish |
2 |
90 |
Katherine Haigh |
1 |
91 |
Anjana Bhat |
1 |
92 |
Susan Conaty-Buck 1) With large tech companies entering the marketplace selling personal health information technology and collecting individual and population health data (Google, Apple, Microsoft and IBM) should these efforts be viewed as another way to help patients and practitioners improve care and access risk, or is having this outside presence disrupting the patient/provider relationship increasing testing, treatments, medication and ultimately cost? 2) With multiple companies rolling out revolutionary artificial intelligence systems to support process automation, cognitive insight and cognitive enagement in healthcare, do we need to redesign what and how we teach our high school and college students? Are colleges and universities going to be the best places for the workers of the future to gain the knowledge and practical experiences needed for success in a digital world? 3) Can the NIH and other healthcare government agencies develop entreprenerial grant programs to match and imbed talented faculty, staff and students in nascent but promising healthcare start-ups to meet the demands for need-driven transformative science and technology? |
1 |
93 |
Esther Biswas-Fiss, Ph.D. |
4 |
94 |
James Schwaber |
1 |
95 |
Theodore DeConne |
1 |
96 |
Valerie Earnshaw |
2 |
97 |
Xiaofeng Yu |
2 |
98 |
Chad Giusti |
2 |
99 |
Ju Young Shin |
1 |
100 |
Cathy Fromen |
1 |
101 |
Kayla Pariser |
1 |
102 |
vishnu marla |
1 |
103 |
Macarena Ramos Gonzalez Dr. Francis Collins, As you may be aware, US institutions are composed of a great number of international students. However, NIH has a lot of restrictions for grant and award submissions/applications those who are neither American citizens, residents nor nationals. Is there any steps you could take for the future so we all can have the same opportunities? Thank you |
1 |
104 |
Lusiana Browning |
1 |
105 |
Bill Farquhar |
1 |
106 |
Mollie Graham |
1 |
107 |
Sam Biswas |
4 |
108 |
Melanie Horning |
1 |
109 |
Mark Lamontia For Dr. Collins. The Intelligent Design community has focused on information in life as positive evidence of a pre-existing designing intelligence for life; in particular, for the origin of first life. Your first book – The Language of God – went in a different direction, and concluded a naturalistic process was responsible for the information content in the cell. Can you explain why you think your position is a better interpretation of the scientific evidence? |
1 |
110 |
Chris Martens |
1 |
111 |
Susan Sheehy |
1 |
112 |
Dawn Elliott |
1 |
113 |
Joan Faull |
1 |
114 |
Randy Wisser |
1 |
115 |
Pia Inguito |
1 |
116 |
Margo Reign |
1 |
117 |
Roberta Golinkoff |
1 |
118 |
Barret Michalec |
0 |
119 |
Norman Wagner Norman |
1 |
120 |
Tammy Anderson What is the future of opioid research funding? How do you envision the level of funding will change and what initiatives or areas of research will be announced? |
4 |
121 |
Stephen Metraux |
1 |
122 |
Richard Johnson |
1 |
123 |
Stan Sandler |
2 |
124 |
carole marks |
1 |
125 |
Soumita Basu |
2 |
126 |
Nicole Ray |
1 |
127 |
Robin Morgan |
1 |
128 |
Beth Miller |
1 |
129 |
Julie Stewart |
1 |
130 |
Kim Bothi |
2 |
131 |
Jacob Wasserman How do we convince people who are skeptical of hard, conclusive science (like with regard to vaccines and climate change) that investment in this is so crucial to our collective well-being? |
2 |
132 |
Rita Patel |
2 |
133 |
Mary Ford |
2 |
134 |
Nike Olabisi |
1 |
135 |
Leta Aljadir |
2 |
136 |
Tracey Holden What do you consider the most urgent health issue of our time (besides climate change) ? |
1 |
137 |
Brandon Bell |
1 |
138 |
Austin Robinson Robinson |
2 |
139 |
Pam Meitner What research is being done on depression in senior citizens? |
2 |
140 |
Stephen DiGiovanni |
1 |
141 |
Edwina Haring |
1 |
142 |
Mary Remmler |
1 |
143 |
Jeffrey Rosen |
1 |
144 |
Marian Palley |
2 |
145 |
Beth Maliner So much damage is being done to families and society by the effects of addiction in this country. Is enough being done to study the neuro chemistry of the brain to really understand addiction and cutting edge treatments? What types of medical research and policy studies are being done now to move treatment in to the 21st century? |
1 |
146 |
Gwen Talham |
1 |
147 |
Susan Williams |
4 |
148 |
Levi Thompson |
1 |
149 |
Madolyn MacDonald |
1 |
150 |
Tim English |
1 |
151 |
Howard Smith |
2 |
152 |
Regina Wright |
3 |
153 |
Karen Johnston |
1 |
154 |
Bill Rambo |
2 |
155 |
Allie Sethman |
2 |
156 |
Marsha Rogers |
1 |
157 |
THOMAS ELEUTERIO |
1 |
158 |
Timothy Dowling |
1 |
159 |
Ruby Harrington For Dr. Francis Collins: What role does the NIH play in ensuring strong intellectual property protections? |
1 |
160 |
Sean O’Neill O’Neill To what extent has NIH and the US Senate advanced the connection between health outcomes and improved pedestrian and bicycle mobility and Smart Growth in the United States? Many studies have shown that current environment and formulas are clearly not working, so what are we doing to fix it through improved policies, regulation, and funding? |
4 |
161 |
Jamie Pedrick |
1 |
162 |
Helen Stimson |
1 |
163 |
Lyn Newsom |
2 |
164 |
Sandra Lewisch |
1 |
165 |
Beth Chajes |
1 |
166 |
Michelle Cirillo |
1 |
167 |
Nicholas Petrelli |
1 |
168 |
Chris Yochim |
1 |
169 |
Michael Dejos |
2 |
170 |
Kate Marshall |
2 |
171 |
Dr Anthony Ragone |
1 |
172 |
Shannon Freeman Freeman |
1 |
173 |
Mary Boggs |
1 |
174 |
Andrew Cottone |
1 |
175 |
Rob Martinelli |
1 |
176 |
Kevin Cameron |
1 |
177 |
Siobhan Hawthorne |
1 |
178 |
Kelli Racca |
2 |
179 |
Anne Kisielewski |
1 |
180 |
Robert L Sassa How do you feel the US is handling the scale-up and commercialization of Cell and Gene Therapies vs. other Governments? |
1 |
181 |
Navin Vij |
1 |
182 |
Joseph Nyangon |
1 |
183 |
Tim Mueller |
1 |
184 |
Heather Barron Barron |
1 |
185 |
Allison Michalowski N/A |
1 |
186 |
Stephen Hyland |
1 |
187 |
Kamila Migdal |
1 |
188 |
David Verrill |
1 |
189 |
Esmaeil Bahalkeh |
1 |
190 |
MICHAEL WIKOL |
2 |
191 |
Ha Le |
1 |
192 |
Mary Rycik I am currently undergoing cancer treatments. I am fortunate that most of my costs are covered under a Medicare supplement plan. What changes would you recommend that would make health care more equitable for all Americans? |
2 |
193 |
John Slater |
1 |
194 |
Murray Johnston |
1 |
195 |
J-P Laurenceau |
2 |
196 |
Velia Fowler |
1 |
197 |
Michael Alexo |
2 |
198 |
Kimberly Williams |
1 |
199 |
Daniel White |
1 |
200 |
Omar Khan |
1 |
201 |
Noel Duckworth Social inequities can mean the difference between life or death, or a life filled with vigor and good health or one plagued with chronic disease and poor health. Given growing evidence that it is these social determinants that contribute the most to health, with only 20% from clinical health care (access and quality), and 30% from health behaviors (themselves largely determined by social and physical environments), wouldn’t it stand that funding efforts addressing inequities and the social determinants of health would stand to have the largest impact on population health? If so, how does our national funding, including the NIH budget for the Population Health Branch reflect this? Are 80% of our investments dedicated to addressing inequities and determinant of health? If not, why? |
1 |
202 |
Darcell Griffith |
2 |
204 |
Melinda Duncan |
1 |
205 |
Ann Lewandowski |
1 |
206 |
Louise Thoma |
1 |
207 |
Dana Mathews |
2 |
208 |
Shaun Sutherell |
1 |
209 |
April Kloxin |
1 |
210 |
Lee Pachter How will the NIH integrate population health perspectives centering on the social determinants of health into their vision for health research? |
1 |
211 |
Kathleen Matt |
1 |
212 |
Jason Jakiela |
1 |
213 |
Rita Landgraf |
1 |
214 |
Lauren Neely |
1 |
215 |
Sangeeta Gupta |
1 |
216 |
Tom Buchanan |
1 |
217 |
John Bertrand |
4 |
218 |
Hiral Master |
1 |
219 |
Chris Manning |
1 |
220 |
Stephen Buchanan |
1 |
221 |
Stephen Lawless |
1 |
222 |
Estella Atekwana |
4 |
223 |
Debra Morris |
2 |
224 |
Levi Thompson |
4 |
225 |
Timothy Fowles Dr. Collins, could you discuss how your belief in God informs your commitments to improving health. |
1 |
226 |
Kristen Bennett |
1 |
227 |
Cindy Bo What would you believe is the biggest transformation in pediatrics in the next 2-3 years? |
1 |
228 |
Franklin Iheanacho There have been great advances in cancer therapies especially in immunotherapy with the utilization of checkpoint blockades and CAR T cells. What do you think will be the next big advancement or paragdim shift in cancer treatment? |
1 |
229 |
Vicky Funanage |
1 |
230 |
Ryan Locke |
1 |
231 |
Sunita Chandrasekaran |
1 |
232 |
Hui Fang |
1 |
233 |
Kathy Janvier |
1 |
234 |
Melissa Skidd |
1 |
235 |
AnnMarie LeNoir |
1 |
236 |
Mark Dobbins |
4 |
237 |
Ann Katorkas |
1 |
238 |
Julie Greenwood |
1 |
239 |
Michael Silvon |
1 |
240 |
George Watson |
1 |
241 |
Ryan Pohlig |
1 |
242 |
Kate Marshall |
2 |
243 |
Michelle Axe |
1 |
244 |
Maria Palazuelos |
2 |
245 |
ADITYA JAGARAPU |
1 |
246 |
HENRY GLYDE |
2 |
247 |
David Martin |
1 |
248 |
Sofia Sanchez Can Dr. Collins address initiatives NIH is carrying out to improve diversity in science? |
1 |
249 |
Robert Bates |
4 |
250 |
Pam G Green Not a question, but a note: Alumna UD class of 1975. Parent of high honors UD graduate, with distinction, class of 2012, Tim Gilpatrick, with major in biochemistry and minor in biochemical engineering. He also sang with the DelTones for four years. After graduation, Tim began a two-year fellowship at NIH, working in Dr. Denardo’s lab. He was among a group of Fellows and staff members who sang and played guitar at a party for Dr. Collins. Dr. Collins played guitar, which bears an inlaid mother-of-pearl double helix. From there Tim was accepted in the MD/PhD program at Johns Hopkins University School of Medicine in Baltimore, MD. Tim is an exceptional student and an exceptional young man. One of these tickets is for Tim, if he can make it. They keep him very busy at JHUSM. Thank you UD and NIH. Pam Gilpatrick Green, ’75. 302.368.4946. |
3 |
251 |
Alfonso Garbayo How far have we come and how far do we need to go for for IntraLinks operability of healthcare data: patient level data across the different settings. |
2 |
252 |
Carly Garbayo |
1 |
253 |
Alfonso Garbayo .. Not sure if my question was submitted. |
1 |
254 |
Karen Hoober |
1 |
255 |
Kelly Morrissey Often times, research and programs are stymied or held hostage from year to year, pending continued government support and funding. What are your thoughts about assuring stable, consistent funding year-upon-year and administration-upon-administration for establishing and continued government support for science and research? |
1 |
256 |
Maria Taylor |
1 |
257 |
Karen Druliner |
2 |
258 |
Lynn Snyder-Mackler |
2 |
259 |
Mike Bowman |
1 |
260 |
Arianna Starost |
1 |
261 |
Megan Wenner |
1 |
262 |
Laure Ergin |
4 |
263 |
Dara Morey |
1 |
264 |
Byung-Chun Yoo |
1 |
265 |
Charlie Tomlinson |
1 |
266 |
Norman Wagner Norman |
1 |
267 |
Jeb Connor Biomarkers and their derivative tests are demonstrating to be very high value to clinicians, patients, payers and biopharma’s; however, in spite of ~2 decades of signficant and increasing investment in new biomarker discovery (mostly tumor-based mutation-based biomarkers) in cancer less than 10% of cancer patients have mutations that can be easily matched to therapies, and in really “hot” immuno-therapy market, mutation-based markers are not effective. How interested would NIH be in a proven disruptive technology that can rapidly discover novel blood-based biomarkers from the immune system (not DNA mutations) that could discriminate between responders vs non-responder to I-0 thereapies, a well as most any therapy for most any disease, PLUS identify pre-symptomatic patients for early disease treatment? Who at NIH is the leader in charge of such interst? Would you provide a warm introduction to him/her for an introductory meeting? |
1 |
268 |
Natalie Kaucic |
1 |
269 |
Stanley Sandler |
2 |
270 |
Pamela Shiao |
1 |
271 |
Faria Sanjana |
1 |
272 |
Grace Hobson |
2 |
273 |
Jordan Patik |
1 |
274 |
Sue Giancola |
1 |
275 |
Melissa Witman |
1 |
276 |
Elissa Katulka |
1 |
277 |
Shani Craighead |
1 |
278 |
Pushpinder Litt |
1 |
279 |
Sienna Pyle |
2 |
280 |
Robert Schmidt What are your plans for Parkinson’s disease. |
0 |
281 |
Shaili Patel |
1 |
282 |
Samuel Scinto |
1 |
283 |
Sophie Guderian |
1 |
284 |
Samantha Cassel |
1 |
285 |
Dan Minahan |
1 |
286 |
Queen Agboye |
1 |
287 |
Dawn Montgomery |
1 |
288 |
Elizabeth Smith |
1 |
289 |
Laura Statts |
2 |
290 |
Xiaoyan Qian |
1 |
291 |
Ada Anyanwu |
1 |
292 |
Caitlin Wood |
1 |
293 |
Shane McGinty |
1 |
294 |
Keely Keller |
1 |
295 |
Hagar Feinstein |
2 |
296 |
Olivia George |
1 |
297 |
Kalaivani Saravanan |
1 |
298 |
Rita Hayford |
1 |
299 |
Camil Diaz |
1 |
300 |
Kiersten McCartney |
1 |
301 |
Carlos Mendoza |
1 |
302 |
Nicole Berzins |
1 |
303 |
Chunling Peng |
1 |
304 |
Heidi Van Every |
1 |
305 |
Laura Welti |
1 |
306 |
Shukla Das |
1 |
307 |
Yuanzhe Guan |
1 |
308 |
Stephanie Becker |
2 |
309 |
Kelly Mulholland |
1 |
310 |
Ohnmar Khanal |
1 |
311 |
Hilary Dean |
1 |
312 |
Allison Miller |
1 |
313 |
Shivanand Venkanna Sheshappanavar |
1 |
314 |
Mike Morris |
1 |
315 |
Monica Mesa |
1 |
317 |
Brendan Lucey |
1 |
318 |
Rakesh Mehta |
2 |
319 |
John Ruano-Salguero Although major diseases such as heart and brain disease can occur randomly, there is mounting evidence that lifestyle and environmental factors can contribute to their onset. What kind of research or infrastructure is needed to lower the number of these potentially preventable diseases in both urban and rural areas. |
1 |
320 |
Adam Morris |
2 |
321 |
Lucas Dunshee For Senator Coons: Is there any bipartisan initiative in the senate to increase the NIH’s annual budget? |
1 |
322 |
ADITYA JAGARAPU JAGARAPU |
1 |
323 |
Jamie Benson |
1 |
324 |
Jennifer Saylor |
1 |
325 |
Andrew Kuczmarski |
1 |
326 |
Hannah Sviridovsky |
1 |
327 |
Samuel Novo |
1 |
328 |
Samuel Keating |
1 |
329 |
Christal Sheppard Senator Coons – Will you introduce and move legislation to change section 101 court precedent regarding products of nature, that make many of the products from BIO members unpatentable? |
1 |
330 |
Sachin Gavali |
1 |
331 |
Henry Chang |
1 |
332 |
Jangwon Kwon |
1 |
333 |
Sanjib Chowdhury |
1 |
334 |
Will Maguire |
1 |
335 |
Gabrielle Foreman |
1 |
336 |
Darlene Sauter |
2 |
337 |
Kaleb Burch Burch |
1 |
338 |
Jessica Johnson |
1 |
339 |
Celeste Dix |
1 |
340 |
Margaret French |
1 |
341 |
Mahbubul Shihan |
1 |
342 |
Danielle Valcourt |
1 |
343 |
Shardae Showell |
1 |
344 |
Rui Wang |
1 |
345 |
Mallory Garnett |
1 |
346 |
Rachel Gilbert |
1 |
347 |
Paige Ruderman |
1 |
348 |
Maria Fernanda Souza Lima |
1 |
349 |
Jerome Lewis |
1 |
350 |
Phoebe Balascio |
1 |
351 |
Aidan Zerdoum |
1 |
352 |
Mic Johns |
1 |
353 |
Thomas Kim |
1 |
354 |
Jacob Capin |
1 |
355 |
Elanna Arhos |
1 |
356 |
Becky Winslow What Pharmacogenomics research is the state of Delaware supporting to discover new no opioid medications for chronic pain based on Genomics and/or better understand how individual responses to medications used in medication assisted therapy for opioid dependence affect short and long term recovery from opioid dependence? |
1 |
357 |
Ellen Bloom |
1 |
358 |
Matina Nicholson Why have you denied equal funding for a hidden health crisis (stayed by cdc) for Myalgic Encephalitis for over 30 years and have the leading academics centers researcher while you find billions into centers of alternative health with no results? Millions are gravely suffering a slow death with no treatment & minimal care (and care is rare for ME in DE? |
1 |
359 |
Dennis Sweitzer |
1 |
360 |
Lauren DePaul |
1 |
361 |
Lisa Pistone |
1 |
362 |
Hilary Weidner |
1 |
363 |
John Stout |
1 |
364 |
Jack Williams |
1 |
365 |
Frederick Rajasekaran |
1 |
366 |
Patience Kelly What are some steps we can take to make research more accessible to the general public? Many people seem to distrust scientists and statistical studies (i.e., vaccines), and those who are curious may have trouble accessing papers, resources, etc they may be interested in. |
1 |
367 |
Rachel Lieser |
1 |
368 |
Eileen Sparling How is the federal government integrating the impact of social determinants of health into the broad approach (not just treatment) for fighting and preventing chronic disease? Thanks! |
1 |
369 |
Chaplin Mazzocchi |
1 |
370 |
Breanna Nicholson |
1 |
371 |
Elizabeth Orsega-Smith |
1 |
372 |
STEPHANIE Williams N/a |
1 |
373 |
Zachary Cox |
1 |
374 |
Ellen Latronico |
2 |
375 |
Talia Dawn Brookstein-Burke |
1 |
376 |
David Bichara |
1 |
377 |
Mandy Minner |
1 |
378 |
Tanya Haley |
1 |
379 |
Manish Chaudhary what role do new technical advances play in the prevention of diseases? |
1 |
380 |
Chris Hamilton |
1 |
381 |
Lola Osawe, FACMPE, FACHE |
1 |
382 |
Bankole Onamusi |
1 |
383 |
Christina Hamdan |
1 |
384 |
Nicholas Collins |
1 |
385 |
Anna Panova |
1 |
386 |
Kathy Costigan |
1 |
387 |
Christine Hillman |
1 |
388 |
Amanda Owen Van Horne |
1 |
389 |
Rachel Clein |
1 |
390 |
Zachary Gemzik |
1 |
391 |
Donna Monroe |
1 |
392 |
Donna Monroe |
1 |
393 |
Curtis Johnson |
1 |
394 |
Tom Powers What do you see as the proper roles and limitations of genomic prediction in law enforcement? |
1 |
395 |
Kristin Jankowski Has the NIH considered adding One Health clinics around the country (we have one up and running at a FQHC in Wilmington in partnership with University of DE and Penn Veterinary School. |
1 |
396 |
Dustin Prusisz |
1 |
397 |
Lauren Tumbelty |
1 |
398 |
Kieran Puffer N/A |
1 |
399 |
Matt Zimmerman |
1 |
400 |
Kenneth Chisholm |
2 |
401 |
Carla Stone What role will telemedicine play in expanding access to health care? Do you believe that it will reduce cost of the delivery of healthcare, particularly of chronic NCDs? What federal legislative or regulatory changes are currently being devised to expand telemedicine across state lines or internationally especially regarding provider standards, licensing and payment for services? |
1 |
402 |
Midge Willard |
1 |
403 |
Jonathan Kirch How focused are America’s policy makers on ending the tobacco problem? |
1 |
404 |
Jeffrey Garland |
2 |
405 |
Gilberto Schleiniger |
2 |
406 |
Christopher Raymond |
1 |
407 |
Peyton Delgorio |
1 |
|
Dennis Assanis |
1 |
408 |
Laurie Ruggiero |
1 |
409 |
Michael Chajes Chajes |
1 |
410 |
Deb Jaisi |
1 |
411 |
Sharon Pitt |
1 |
412 |
Keith Schneider |
1 |
413 |
Tracey Holden What do you see as the most critical area of research in the near term – five to ten years out? |
1 |
414 |
Lucy Hiscox |
1 |
415 |
Gilberto Schleiniger |
2 |
416 |
Andrew Dinsmore |
1 |
417 |
Jason Fischel |
1 |
418 |
Andrew Wilson Can you describe the role of the NIH and its funding as it complements, supplements, or replacing private pharmaceutical R&D? |
2 |
419 |
Daniel Malley |
1 |
420 |
Mark Keigi On the medical residency shortage, what’s the directors and senators position ? |
1 |
421 |
Don Shaffer Shaffer |
1 |
422 |
Catrina Jefferson |
1 |
423 |
William Simpson |
1 |
424 |
Catrina Jefferson Which organizations, governments or partnerships are seeing successful, meaningful results in their methods to reduce addiction (and ultimately fatalities) in the community? How is their approach different + how are they measuring results? |
1 |
425 |
Pushpinder Litt |
1 |
426 |
Jaanvi Mehta |
1 |
427 |
Louise Johnson |
1 |
428 |
Gilberto Schleiniger |
2 |
429 |
Gilberto Schleiniger |
2 |